Shattuck Labs (NASDAQ:STTK) Earns Neutral Rating from HC Wainwright

Shattuck Labs (NASDAQ:STTK)‘s stock had its “neutral” rating reaffirmed by investment analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.54) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

STTK has been the topic of a number of other research reports. Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a report on Wednesday, October 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research note on Thursday. Finally, Citigroup cut Shattuck Labs from a “buy” rating to a “neutral” rating and cut their price target for the stock from $8.00 to $2.00 in a research note on Wednesday, October 2nd. Four research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.67.

Shattuck Labs Price Performance

Shares of Shattuck Labs stock opened at $1.24 on Friday. Shattuck Labs has a 1 year low of $1.07 and a 1 year high of $11.76. The company’s fifty day moving average is $2.08 and its two-hundred day moving average is $4.23.

Insider Activity

In related news, CEO Taylor Schreiber purchased 36,500 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was acquired at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the acquisition, the chief executive officer now directly owns 71,002 shares of the company’s stock, valued at $85,912.42. This trade represents a 105.79 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC raised its holdings in Shattuck Labs by 4.8% during the first quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after purchasing an additional 1,788 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Shattuck Labs by 38.2% during the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock worth $16,270,000 after buying an additional 502,860 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Shattuck Labs in the 1st quarter worth about $113,000. Bank of New York Mellon Corp increased its stake in shares of Shattuck Labs by 209.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after purchasing an additional 150,340 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its holdings in Shattuck Labs by 15.0% during the 2nd quarter. Pinnacle Associates Ltd. now owns 599,423 shares of the company’s stock valued at $2,314,000 after buying an additional 78,177 shares during the last quarter. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.